Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

First CAR T-Cell Therapies OK'd In EU: Novartis's Kymriah And Kite's Yescarta

Executive Summary

The European Medicines Agency's drug evaluation committee, the CHMP, has recommended nine products for marketing authorization in the EU, including the first two CAR T-cell therapies, Novartis's Kymriah and Kite Pharma's Yescarta, as well as four other orphan drugs.
Advertisement

Related Content

Gilead And Novartis Unveil EU Marketing Plans For CAR-T Therapies, But Hurdles Remain
EU Accelerated Assessment Tracker: Rejection Is Standard Outcome For Fast-Track Requests This Year
A Massive First For EU – CAR-T Therapies Kymriah and Yescarta Hoping For CHMP OK
Liver Damage Worries Lead To Further EU Restrictions On Richter’s Esmya

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS123398

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel